J. Jac

958 total citations
25 papers, 755 citations indexed

About

J. Jac is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, J. Jac has authored 25 papers receiving a total of 755 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 10 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in J. Jac's work include Renal cell carcinoma treatment (10 papers), Cancer Genomics and Diagnostics (8 papers) and Liver physiology and pathology (6 papers). J. Jac is often cited by papers focused on Renal cell carcinoma treatment (10 papers), Cancer Genomics and Diagnostics (8 papers) and Liver physiology and pathology (6 papers). J. Jac collaborates with scholars based in United States, United Kingdom and Switzerland. J. Jac's co-authors include Robert J. Amato, J. P. Willis, Somyata Saxena, Joan Hernandez-McClain, R. J. Amato, Richard Harrop, Stuart Naylor, Francis Payumo, Monette Cotreau and William Shingler and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

J. Jac

25 papers receiving 747 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Jac United States 15 424 423 222 206 109 25 755
Hiroomi Tada United States 9 397 0.9× 365 0.9× 537 2.4× 146 0.7× 104 1.0× 13 951
D Bigini Italy 12 366 0.9× 478 1.1× 452 2.0× 244 1.2× 61 0.6× 17 945
Weikai Xiao China 18 265 0.6× 425 1.0× 477 2.1× 473 2.3× 213 2.0× 37 1.1k
Marina Baretti United States 13 293 0.7× 367 0.9× 531 2.4× 333 1.6× 89 0.8× 50 969
Yuqi Wang China 10 265 0.6× 222 0.5× 389 1.8× 194 0.9× 76 0.7× 30 746
H Sawada Japan 15 404 1.0× 669 1.6× 503 2.3× 187 0.9× 137 1.3× 39 1.3k
Liangqing Dong China 13 160 0.4× 272 0.6× 258 1.2× 189 0.9× 156 1.4× 22 736
Zachary R. Chalmers United States 15 580 1.4× 649 1.5× 584 2.6× 349 1.7× 73 0.7× 35 1.4k
J.M.G.H. van Riel Netherlands 14 415 1.0× 199 0.5× 720 3.2× 382 1.9× 132 1.2× 25 989
Haiqing Ma China 17 211 0.5× 511 1.2× 425 1.9× 321 1.6× 38 0.3× 27 965

Countries citing papers authored by J. Jac

Since Specialization
Citations

This map shows the geographic impact of J. Jac's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Jac with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Jac more than expected).

Fields of papers citing papers by J. Jac

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Jac. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Jac. The network helps show where J. Jac may publish in the future.

Co-authorship network of co-authors of J. Jac

This figure shows the co-authorship network connecting the top 25 collaborators of J. Jac. A scholar is included among the top collaborators of J. Jac based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Jac. J. Jac is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elez, Élena, Dale R. Shepard, Cristina Smolenschi, Tanios Bekaii‐Saab, & J. Jac. (2023). P-58 An ongoing open-label, phase 2 trial of RP2 Or RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma. Annals of Oncology. 34. S34–S35. 1 indexed citations
2.
Lim, Wan‐Teck, Myung‐Ju Ahn, Quan‐Sing Ng, et al.. (2018). Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. Clinical Pharmacology in Drug Development. 7(5). 532–542. 15 indexed citations
3.
Patnaik, Amita, Glen J. Weiss, K. Papadopoulos, et al.. (2014). Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. British Journal of Cancer. 111(2). 272–280. 37 indexed citations
4.
5.
Patnaik, Amita, Glen J. Weiss, K. Papadopoulos, et al.. (2010). Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 2525–2525. 30 indexed citations
6.
7.
Amato, Robert J., William Shingler, Jackie de Belin, et al.. (2009). Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α). Journal of Immunotherapy. 32(7). 765–772. 55 indexed citations
8.
Amato, Robert J., J. Jac, & Joan Hernandez-McClain. (2008). Interferon-α in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial. Anti-Cancer Drugs. 19(5). 527–533. 6 indexed citations
9.
Amato, Robert J., J. Jac, & Joan Hernandez-McClain. (2008). Motexafin Gadolinium for the Treatment of Metastatic Renal Cell Carcinoma: Phase II Study Results. Clinical Genitourinary Cancer. 6(2). 73–78. 22 indexed citations
10.
Amato, Robert J., Noel Drury, Stuart Naylor, et al.. (2008). Vaccination of Prostate Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax). Journal of Immunotherapy. 31(6). 577–585. 44 indexed citations
11.
Amato, Robert J., et al.. (2008). Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer. Clinical Genitourinary Cancer. 6(2). 97–102. 44 indexed citations
12.
13.
Amato, R. J., et al.. (2008). A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC). Journal of Clinical Oncology. 26(15_suppl). 14603–14603. 9 indexed citations
14.
Bloch, C., et al.. (2007). The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomedical Imaging and Intervention Journal. 3(1). e6–e6. 64 indexed citations
15.
Amato, R. J., Martin L. Dalton, Qihui Zhai, et al.. (2007). A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). Journal of Clinical Oncology. 25(18_suppl). 5026–5026. 67 indexed citations
16.
Jac, J., et al.. (2007). A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Journal of Clinical Oncology. 25(18_suppl). 5107–5107. 43 indexed citations
17.
Amato, Robert J. & J. Jac. (2006). Targeted Anti-Cancer Therapies for Renal Cancer. Drugs. 66(17). 2161–2171. 6 indexed citations
18.
Jac, J., et al.. (2006). Rapamycin for androgen-independent prostrate cancer (AIPC). Journal of Clinical Oncology. 24(18_suppl). 14584–14584. 7 indexed citations
19.
Jac, J., et al.. (2006). Interferon-alpha (INF) and gefitinib or imatinib in patients (pts) with metastatic renal cell carcinoma (RCC). Journal of Clinical Oncology. 24(18_suppl). 14616–14616. 1 indexed citations
20.
Jac, J., et al.. (2005). Phase II trial of motexafin gadolinium (MGd) for treatment of metastatic renal cell carcinoma (MRCC). Journal of Clinical Oncology. 23(16_suppl). 4724–4724. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroomi Tada Breakdown of academic impact, for papers by D Bigini Breakdown of academic impact, for papers by Weikai Xiao Breakdown of academic impact, for papers by Marina Baretti Breakdown of academic impact, for papers by Yuqi Wang Breakdown of academic impact, for papers by H Sawada Breakdown of academic impact, for papers by Liangqing Dong Breakdown of academic impact, for papers by Zachary R. Chalmers Breakdown of academic impact, for papers by J.M.G.H. van Riel Breakdown of academic impact, for papers by Haiqing Ma
Rankless by CCL
2026